CZS-241 is an orally active, selective Polo-like kinase (PLK) 4 inhibitor (IC50 = 2.6 nM) with additional inhibitory activity against TRKA (IC50 = 2.74 μM); it induces apoptosis and arrests the cell cycle at the S/G2 phase; it exhibits potent anti-proliferative activity against leukemia cell lines while showing safety toward normal cell lines.